NasdaqBiological Products, (No Diagnostic Substances)

Argenx SE ARGX

Price

Full chart with drawing tools and indicators
Valuation and ratios (P/E, margins, market value)

Price charts and figures by TradingView, shown in a sealed box: it cannot read this page, but TradingView may count your visit. Prices can be delayed.

Results from SEC filings

Net income$1.3B+55%FY ending Dec 31, 2025
Research & development$1.4B+39%FY ending Dec 31, 2025

Insider trades

No insider trades reported in the last 12 months.

Trades by members of Congress

1 member reported 3 buys and 0 sales since Oct 14, 2026. Amounts are legal ranges, not exact figures.

MemberTradeAmountTradedReportedOwner
Gilbert Ray Cisneros, Jr. DBought$1,001–$15KOct 27, 2026Nov 10, 2026Self
Gilbert Ray Cisneros, Jr. DBought$1,001–$15KOct 15, 2026Nov 10, 2026Self
Gilbert Ray Cisneros, Jr. DBought$15K–$50KOct 14, 2026Nov 10, 2026Self

Latest SEC filings

All filings on SEC EDGAR ↗

About Argenx SE

Business description
Industry
Biological Products, (No Diagnostic Substances)
Sector
Life Sciences
Headquarters
Zwijnaarde
Incorporated in
Netherlands
Fiscal year ends
December 31
Exchange
Nasdaq
Filer size
Large accelerated filer
Formerly
argenx N.V
SEC company number (CIK)
1697862

Company figures and insider trades: U.S. Securities and Exchange Commission (EDGAR). Congress trades: Clerk of the U.S. House of Representatives. Nebula is not affiliated with either and this page is not investment advice.